



PRESSRELEASE

Lund, August 22, 2024

Invitation to monthly digital events and presentations of quarterly reports

Hamlet BioPharma is pleased to announce the continuation of the digital event series this autumn. These events provide participants a valuable opportunity to follow and discuss our drug development process and engage directly with our team during the Q&A sessions that will follow each presentation. Please visit our web page to join the digital events: <https://hamletbiopharma.com/series-of-digital-events-2024/>

The digital event are scheduled for:

- September 18th, 2024, 12:00 CET
- October 23rd, 2024, 12:00 CET
- December 11th, 2024, 12:00 CET

Additionally, please note the following dates for quarterly reports:

- August 28th, 2024: Year-End Report (Q4) 2023/2024
- October 31st, 2024: Annual Report 2023/2024
- November 15th, 2024: Quarterly Report (Q1) 2024/2025

We would also like to inform you that the Annual General Meeting 2023/2024 is scheduled for November 21st, 2024 to be held in Malmö, Sweden.

To receive information from the company, please subscribe at <https://hamletbiopharma.com/subscribe/>.

For more information please contact:

Martin Erixon, CEO, Hamlet BioPharma AB, +46 733 00 43 77
martin.erixon@hamletpharma.com

Catharina Svanborg, Chairman of the board, Hamlet BioPharma AB, +46 709 42 65 49,
catharina.svanborg@hamletpharma.com